The global overactive bladder treatment market is projected to reach USD 4.95 Billion by 2027 from USD 3.97 Billion in 2020; at a CAGR of 3.2 %. Overactive bladder treatment includes various therapies used to treat the sudden, involuntary contraction of the muscle in the urinary bladder wall. This contraction leads to urgency to urinate, risen frequency of urinating, nocturia, and urge-incontinence.
Anticholinergic agents are considered as the first line treatment for overactive bladder disorders. Flavoxate, oxybutynin, tolterodine are some of the generic drugs used for the treatment of overactive bladder. These drugs acts by antagonizing cholinergic receptors that provides the relief from the frequent urination. Increasing population diagnosed with overactive bladder disorder coupled with aging population will drive the growth of this market. Furthermore, manufacturers are continuously increasing their research and development expenditure to develop novel drugs such as neuromuscular blocking agents with innovative mechanism of actions. This factor will provide healthy platform to develop this market and hence drives the market growth. In addition, efforts of many key players launching consumer campaigns aiming to increase the awareness of this disorder among the people will further boost the growth of this market. However, patent expiry of the key drugs namely Oxytrol, Toviaz and Detrol may significantly restrain the growth of this market. Unfavourable side effect such as bladder muscle contraction, mental confusion, dry mouth and constipation coupled with low efficacy of available drugs will also restrain the growth of this market.
Major players operating in the global overactive bladder treatment market are AstellasPharma, Inc., Allergan, Plc, AurobindoPharma Limited, Pfizer, Inc., Teva Pharmaceutical Industries Limited, Medtronic plc, Mylan N.V., Endo International plc, and Hisamitsu Pharmaceutical Co., Inc.
The global overactive bladder treatment market consists of four regions, namely, the Americas, Europe, Asia-Pacific, and the Middle East and Africa. North America is anticipated to dominate the market in the Americas owing to the increasing geriatric population, growing occurrences of OAB, and the availability of numerous healthcare coverage systems such as Medicare.
Europe is anticipated to hold the second position in the global overactive bladder treatment market. It is estimated that the market growth in this region is attributed to the rising incidences of OAB and availability of reimbursement for certain treatment options. For instance, the UK’s National Institutes for Health and Care Excellence (NICE) provides reimbursement for the Botox therapy.
The overactive bladder treatment market in Asia-Pacific consists of countries, namely, China, Japan, the Republic of Korea, India, Australia, and the rest of Asia-Pacific. The Asia-Pacific region is expected to be the fastest growing region owing to the growing prevalence of bladder overactivity, rising geriatric population, rising healthcare expenditure, and increasing awareness about overactive bladder condition.
The Middle East and Africa are likely to hold the least share in the global overactive bladder treatment market. In this region, the Middle East is expected to dominate owing to the rising healthcare expenditure and rising occurrences of neurological diseases, especially among the aged population.
Report : Overactive Bladder Treatment Market - By Pharmacotherapy (Anticholinergics, SolifenacinOxybutynin, Darifenacin, Fesoterodine, Tolterodine, Trospium, Other Anticholinergics, Mirabegron, BOTOX, Neurostimulation, Other) By Disease Type (Idiopathic Bladder Overactivity, Neurogenic Bladder Overactivity) By Region (North America, Europe, Asia-Pacific, RoW) - Industry Analysis, Opportunity and Forecast 2020 To 2027